| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electrocardiography | 189 | 2024 | 957 | 31.390 |
Why?
|
| Myocardial Infarction | 165 | 2023 | 1000 | 21.460 |
Why?
|
| ST Elevation Myocardial Infarction | 30 | 2024 | 105 | 12.630 |
Why?
|
| Myocardial Reperfusion Injury | 37 | 2022 | 144 | 9.950 |
Why?
|
| Myocardial Ischemia | 40 | 2022 | 332 | 7.290 |
Why?
|
| Bundle-Branch Block | 18 | 2024 | 35 | 6.300 |
Why?
|
| Acute Coronary Syndrome | 17 | 2024 | 202 | 5.830 |
Why?
|
| Pacemaker, Artificial | 14 | 2024 | 172 | 4.980 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 26 | 2022 | 714 | 4.950 |
Why?
|
| Myocardium | 43 | 2023 | 985 | 4.850 |
Why?
|
| Heptanoic Acids | 17 | 2008 | 77 | 3.910 |
Why?
|
| Cardiac Pacing, Artificial | 13 | 2024 | 114 | 3.850 |
Why?
|
| Glucosides | 8 | 2024 | 46 | 3.670 |
Why?
|
| Pyrroles | 17 | 2008 | 177 | 3.600 |
Why?
|
| Benzhydryl Compounds | 8 | 2024 | 67 | 3.580 |
Why?
|
| Coronary Occlusion | 8 | 2023 | 27 | 3.520 |
Why?
|
| Cardiotonic Agents | 11 | 2024 | 135 | 3.410 |
Why?
|
| Pericarditis | 7 | 2022 | 42 | 3.340 |
Why?
|
| Adenosine | 15 | 2022 | 126 | 3.250 |
Why?
|
| Atrial Fibrillation | 13 | 2024 | 626 | 3.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 16 | 2024 | 1230 | 3.200 |
Why?
|
| Thrombolytic Therapy | 37 | 2020 | 203 | 3.120 |
Why?
|
| Coronary Angiography | 42 | 2024 | 417 | 3.000 |
Why?
|
| Heart Rate | 13 | 2020 | 586 | 2.890 |
Why?
|
| Coronary Vessels | 19 | 2023 | 526 | 2.880 |
Why?
|
| Coronary Artery Disease | 20 | 2024 | 747 | 2.880 |
Why?
|
| Thiazolidinediones | 11 | 2012 | 79 | 2.840 |
Why?
|
| Percutaneous Coronary Intervention | 12 | 2024 | 228 | 2.820 |
Why?
|
| Cardiovascular Agents | 7 | 2023 | 86 | 2.720 |
Why?
|
| Humans | 329 | 2024 | 123053 | 2.660 |
Why?
|
| Cyclooxygenase 2 | 15 | 2016 | 158 | 2.640 |
Why?
|
| Platelet Aggregation Inhibitors | 13 | 2024 | 257 | 2.560 |
Why?
|
| Cardiovascular Diseases | 13 | 2023 | 1862 | 2.560 |
Why?
|
| Diagnosis, Differential | 36 | 2024 | 1876 | 2.520 |
Why?
|
| Ventricular Function, Left | 20 | 2022 | 494 | 2.360 |
Why?
|
| Hypoglycemic Agents | 12 | 2022 | 426 | 2.260 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 5 | 2019 | 25 | 2.170 |
Why?
|
| Heart Conduction System | 14 | 2023 | 145 | 2.160 |
Why?
|
| Aspirin | 15 | 2022 | 224 | 2.130 |
Why?
|
| Angioplasty, Balloon, Coronary | 24 | 2016 | 172 | 2.120 |
Why?
|
| Male | 217 | 2024 | 60073 | 2.120 |
Why?
|
| Myocardial Reperfusion | 16 | 2011 | 73 | 2.050 |
Why?
|
| Heart Ventricles | 17 | 2021 | 760 | 2.030 |
Why?
|
| Defibrillators, Implantable | 5 | 2019 | 192 | 2.020 |
Why?
|
| Chest Pain | 11 | 2023 | 124 | 2.000 |
Why?
|
| Ventricular Dysfunction, Left | 13 | 2024 | 359 | 1.980 |
Why?
|
| Heart Atria | 8 | 2020 | 313 | 1.980 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 6 | 2022 | 45 | 1.950 |
Why?
|
| Coronary Stenosis | 6 | 2023 | 70 | 1.910 |
Why?
|
| Echocardiography | 26 | 2022 | 1049 | 1.880 |
Why?
|
| Tetrazoles | 7 | 2021 | 63 | 1.850 |
Why?
|
| Aged | 110 | 2024 | 19088 | 1.820 |
Why?
|
| Middle Aged | 139 | 2022 | 25987 | 1.800 |
Why?
|
| Heart | 18 | 2023 | 723 | 1.660 |
Why?
|
| Coronary Circulation | 17 | 2019 | 209 | 1.660 |
Why?
|
| Coronary Disease | 19 | 2007 | 637 | 1.660 |
Why?
|
| Animals | 95 | 2023 | 33785 | 1.650 |
Why?
|
| Rats, Sprague-Dawley | 25 | 2022 | 1213 | 1.640 |
Why?
|
| Inflammasomes | 7 | 2021 | 150 | 1.620 |
Why?
|
| Heart Failure | 16 | 2024 | 2127 | 1.610 |
Why?
|
| Equipment Failure | 7 | 2017 | 122 | 1.540 |
Why?
|
| Tachycardia, Supraventricular | 3 | 2019 | 107 | 1.540 |
Why?
|
| Tachycardia, Ventricular | 10 | 2020 | 197 | 1.520 |
Why?
|
| Dipyridamole | 4 | 2021 | 29 | 1.490 |
Why?
|
| Nitric Oxide Synthase Type III | 12 | 2014 | 220 | 1.490 |
Why?
|
| Rats | 29 | 2022 | 3653 | 1.480 |
Why?
|
| Lipoxins | 8 | 2016 | 12 | 1.420 |
Why?
|
| Anterior Wall Myocardial Infarction | 4 | 2018 | 11 | 1.390 |
Why?
|
| Inferior Wall Myocardial Infarction | 4 | 2020 | 8 | 1.390 |
Why?
|
| Proto-Oncogene Proteins c-akt | 12 | 2021 | 488 | 1.380 |
Why?
|
| Stroke | 7 | 2021 | 955 | 1.370 |
Why?
|
| Anticoagulants | 8 | 2024 | 581 | 1.370 |
Why?
|
| Ventricular Remodeling | 5 | 2020 | 174 | 1.330 |
Why?
|
| Risk Assessment | 20 | 2023 | 3316 | 1.320 |
Why?
|
| Ultrasonic Therapy | 11 | 2007 | 31 | 1.310 |
Why?
|
| Coronary Thrombosis | 8 | 2020 | 33 | 1.310 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 6 | 2021 | 111 | 1.310 |
Why?
|
| Diagnosis, Computer-Assisted | 5 | 2016 | 93 | 1.300 |
Why?
|
| Female | 151 | 2024 | 65520 | 1.270 |
Why?
|
| Arrhythmias, Cardiac | 11 | 2023 | 459 | 1.270 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2021 | 151 | 1.240 |
Why?
|
| Diabetic Nephropathies | 2 | 2021 | 110 | 1.240 |
Why?
|
| Nitric Oxide Synthase Type II | 8 | 2010 | 94 | 1.220 |
Why?
|
| Drug Therapy, Combination | 18 | 2024 | 1140 | 1.220 |
Why?
|
| Prognosis | 44 | 2022 | 4513 | 1.210 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2020 | 210 | 1.180 |
Why?
|
| Myocytes, Cardiac | 13 | 2020 | 618 | 1.160 |
Why?
|
| Apoptosis | 12 | 2023 | 1781 | 1.160 |
Why?
|
| Coronary Artery Bypass | 12 | 2019 | 487 | 1.160 |
Why?
|
| Atrial Flutter | 2 | 2020 | 32 | 1.150 |
Why?
|
| Predictive Value of Tests | 30 | 2020 | 2109 | 1.150 |
Why?
|
| Ventricular Premature Complexes | 3 | 2017 | 10 | 1.150 |
Why?
|
| Thrombosis | 11 | 2020 | 520 | 1.130 |
Why?
|
| Severity of Illness Index | 17 | 2020 | 2846 | 1.120 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2020 | 121 | 1.120 |
Why?
|
| Sensitivity and Specificity | 26 | 2019 | 2014 | 1.120 |
Why?
|
| Ischemic Preconditioning, Myocardial | 4 | 2021 | 10 | 1.110 |
Why?
|
| Heart Diseases | 7 | 2020 | 482 | 1.100 |
Why?
|
| Echocardiography, Stress | 3 | 2019 | 15 | 1.080 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 1256 | 1.080 |
Why?
|
| Wolff-Parkinson-White Syndrome | 4 | 2021 | 73 | 1.080 |
Why?
|
| Disease Models, Animal | 31 | 2023 | 4284 | 1.050 |
Why?
|
| Ventricular Septum | 2 | 2023 | 16 | 1.050 |
Why?
|
| Cardiomyopathies | 3 | 2022 | 478 | 1.010 |
Why?
|
| Randomized Controlled Trials as Topic | 13 | 2022 | 1068 | 1.010 |
Why?
|
| Fibrinolytic Agents | 17 | 2022 | 198 | 1.000 |
Why?
|
| Algorithms | 11 | 2021 | 1592 | 0.980 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 6 | 2012 | 160 | 0.980 |
Why?
|
| Adrenergic beta-Antagonists | 8 | 2022 | 233 | 0.970 |
Why?
|
| AMP-Activated Protein Kinases | 5 | 2021 | 165 | 0.960 |
Why?
|
| Diagnostic Errors | 6 | 2014 | 327 | 0.960 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 3 | 2014 | 7 | 0.960 |
Why?
|
| Hypertrophy, Left Ventricular | 7 | 2020 | 106 | 0.950 |
Why?
|
| Risk Factors | 41 | 2022 | 10012 | 0.950 |
Why?
|
| Aortic Valve Stenosis | 4 | 2023 | 330 | 0.940 |
Why?
|
| Phosphorylation | 16 | 2020 | 1608 | 0.940 |
Why?
|
| Peptides | 8 | 2016 | 794 | 0.930 |
Why?
|
| Diabetes Mellitus, Experimental | 7 | 2019 | 135 | 0.930 |
Why?
|
| Hydrazones | 1 | 2024 | 19 | 0.920 |
Why?
|
| MicroRNAs | 6 | 2019 | 827 | 0.920 |
Why?
|
| Treatment Outcome | 42 | 2023 | 12119 | 0.920 |
Why?
|
| Sodium-Glucose Transporter 2 | 4 | 2023 | 17 | 0.910 |
Why?
|
| Dipeptidyl Peptidase 4 | 3 | 2019 | 22 | 0.910 |
Why?
|
| Hypertension, Pulmonary | 2 | 2020 | 434 | 0.910 |
Why?
|
| Pyridazines | 1 | 2024 | 49 | 0.900 |
Why?
|
| Anticholesteremic Agents | 5 | 2019 | 230 | 0.900 |
Why?
|
| Myocardial Revascularization | 6 | 2019 | 96 | 0.890 |
Why?
|
| Up-Regulation | 10 | 2018 | 862 | 0.890 |
Why?
|
| Hemodynamics | 8 | 2024 | 845 | 0.890 |
Why?
|
| Streptokinase | 14 | 2004 | 20 | 0.860 |
Why?
|
| Eicosanoids | 3 | 2012 | 13 | 0.840 |
Why?
|
| Venoms | 2 | 2013 | 20 | 0.830 |
Why?
|
| No-Reflow Phenomenon | 2 | 2019 | 9 | 0.830 |
Why?
|
| PTEN Phosphohydrolase | 6 | 2014 | 269 | 0.830 |
Why?
|
| Pericarditis, Constrictive | 1 | 2022 | 4 | 0.830 |
Why?
|
| Syncope | 4 | 2016 | 52 | 0.820 |
Why?
|
| Rosuvastatin Calcium | 3 | 2017 | 41 | 0.820 |
Why?
|
| Triazoles | 3 | 2014 | 138 | 0.820 |
Why?
|
| Action Potentials | 4 | 2020 | 501 | 0.810 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 4 | 2022 | 65 | 0.810 |
Why?
|
| Atrioventricular Block | 2 | 2020 | 39 | 0.810 |
Why?
|
| Reproducibility of Results | 17 | 2019 | 2825 | 0.800 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2021 | 1682 | 0.800 |
Why?
|
| Digitalis | 1 | 2021 | 3 | 0.790 |
Why?
|
| Aged, 80 and over | 24 | 2024 | 6369 | 0.780 |
Why?
|
| Ischemic Postconditioning | 1 | 2021 | 4 | 0.770 |
Why?
|
| Vitamin K | 2 | 2024 | 35 | 0.770 |
Why?
|
| Time Factors | 32 | 2023 | 6222 | 0.770 |
Why?
|
| Adamantane | 2 | 2018 | 6 | 0.750 |
Why?
|
| Acute Disease | 11 | 2020 | 1093 | 0.750 |
Why?
|
| Insulins | 1 | 2021 | 17 | 0.740 |
Why?
|
| Ischemia | 5 | 2022 | 344 | 0.730 |
Why?
|
| Simvastatin | 4 | 2010 | 75 | 0.730 |
Why?
|
| Dipeptides | 2 | 2018 | 56 | 0.730 |
Why?
|
| Intermittent Claudication | 1 | 2021 | 55 | 0.720 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2011 | 51 | 0.720 |
Why?
|
| Antifibrinolytic Agents | 1 | 2020 | 33 | 0.710 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2020 | 22 | 0.690 |
Why?
|
| Administration, Oral | 9 | 2021 | 669 | 0.690 |
Why?
|
| Foreign-Body Migration | 2 | 2018 | 73 | 0.690 |
Why?
|
| Retrospective Studies | 42 | 2023 | 16036 | 0.690 |
Why?
|
| Patient Admission | 8 | 2007 | 184 | 0.670 |
Why?
|
| Linagliptin | 1 | 2019 | 4 | 0.670 |
Why?
|
| Diabetic Cardiomyopathies | 4 | 2020 | 15 | 0.670 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 95 | 0.660 |
Why?
|
| Blood Coagulation | 6 | 2002 | 119 | 0.660 |
Why?
|
| Editorial Policies | 1 | 2020 | 52 | 0.660 |
Why?
|
| Ultrasonography, Interventional | 8 | 2002 | 195 | 0.650 |
Why?
|
| Microcirculation | 1 | 2019 | 93 | 0.650 |
Why?
|
| Data Display | 1 | 2019 | 11 | 0.640 |
Why?
|
| Sodium-Hydrogen Exchanger 1 | 1 | 2018 | 3 | 0.640 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 197 | 0.640 |
Why?
|
| Gastrointestinal Hemorrhage | 4 | 2024 | 223 | 0.640 |
Why?
|
| Outpatients | 1 | 2021 | 253 | 0.630 |
Why?
|
| Heart Neoplasms | 2 | 2019 | 100 | 0.630 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 186 | 0.620 |
Why?
|
| PPAR gamma | 4 | 2017 | 91 | 0.620 |
Why?
|
| Signal Processing, Computer-Assisted | 6 | 2019 | 120 | 0.620 |
Why?
|
| Sulfonamides | 4 | 2014 | 259 | 0.620 |
Why?
|
| Electric Countershock | 2 | 2017 | 67 | 0.620 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2022 | 3544 | 0.590 |
Why?
|
| Stroke Volume | 11 | 2022 | 445 | 0.590 |
Why?
|
| Incretins | 1 | 2018 | 25 | 0.580 |
Why?
|
| Glucagon-Like Peptide 1 | 3 | 2012 | 68 | 0.580 |
Why?
|
| Signal Transduction | 19 | 2020 | 4490 | 0.580 |
Why?
|
| Kidney | 4 | 2021 | 1335 | 0.580 |
Why?
|
| Guideline Adherence | 1 | 2020 | 374 | 0.580 |
Why?
|
| Cyclic AMP | 3 | 2012 | 247 | 0.570 |
Why?
|
| Tachycardia | 1 | 2017 | 68 | 0.570 |
Why?
|
| Pulmonary Heart Disease | 1 | 2017 | 4 | 0.570 |
Why?
|
| Ischemic Preconditioning | 3 | 2019 | 18 | 0.560 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2017 | 13 | 0.560 |
Why?
|
| Triage | 3 | 2014 | 140 | 0.560 |
Why?
|
| Artifacts | 3 | 2007 | 104 | 0.550 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 195 | 0.550 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2017 | 28 | 0.550 |
Why?
|
| Tissue Plasminogen Activator | 11 | 2004 | 111 | 0.550 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 4 | 2010 | 94 | 0.540 |
Why?
|
| Cardiomegaly | 1 | 2017 | 133 | 0.530 |
Why?
|
| Cyclooxygenase Inhibitors | 5 | 2007 | 63 | 0.530 |
Why?
|
| Mice | 18 | 2023 | 17534 | 0.530 |
Why?
|
| Receptors, Glucagon | 2 | 2013 | 29 | 0.530 |
Why?
|
| Diabetic Angiopathies | 1 | 2016 | 59 | 0.520 |
Why?
|
| Adult | 48 | 2022 | 29006 | 0.520 |
Why?
|
| Aneurysm, False | 3 | 2006 | 102 | 0.510 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2021 | 279 | 0.510 |
Why?
|
| Cardiac Catheterization | 6 | 2018 | 631 | 0.510 |
Why?
|
| Angina, Unstable | 4 | 2006 | 52 | 0.510 |
Why?
|
| Clinical Trials as Topic | 4 | 2018 | 1084 | 0.500 |
Why?
|
| Immunoblotting | 6 | 2012 | 312 | 0.500 |
Why?
|
| Sick Sinus Syndrome | 2 | 2014 | 12 | 0.500 |
Why?
|
| Coronary Vasospasm | 2 | 2014 | 10 | 0.500 |
Why?
|
| Dyspnea | 3 | 2013 | 147 | 0.490 |
Why?
|
| Heart Aneurysm | 3 | 2011 | 38 | 0.490 |
Why?
|
| Fibroblasts | 2 | 2018 | 880 | 0.480 |
Why?
|
| Drug Interactions | 7 | 2024 | 253 | 0.480 |
Why?
|
| Atrial Premature Complexes | 1 | 2014 | 1 | 0.480 |
Why?
|
| Fluorobenzenes | 1 | 2014 | 38 | 0.470 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 3 | 2014 | 60 | 0.460 |
Why?
|
| Postoperative Complications | 7 | 2019 | 3015 | 0.460 |
Why?
|
| Biomedical Research | 1 | 2020 | 517 | 0.460 |
Why?
|
| Phospholipases A2, Cytosolic | 2 | 2011 | 2 | 0.450 |
Why?
|
| Diabetes Complications | 3 | 2014 | 196 | 0.450 |
Why?
|
| Sinoatrial Block | 1 | 2013 | 1 | 0.450 |
Why?
|
| Hydroxyethyl Starch Derivatives | 3 | 2003 | 8 | 0.450 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 90 | 0.440 |
Why?
|
| Drug Discovery | 1 | 2015 | 170 | 0.430 |
Why?
|
| Technetium Tc 99m Sestamibi | 7 | 2005 | 25 | 0.430 |
Why?
|
| Hospital Mortality | 11 | 2022 | 1009 | 0.430 |
Why?
|
| Enzyme Activation | 5 | 2020 | 617 | 0.430 |
Why?
|
| Heart Block | 3 | 2016 | 40 | 0.430 |
Why?
|
| Stents | 7 | 2018 | 872 | 0.420 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 5 | 2014 | 10 | 0.420 |
Why?
|
| Arachidonate 5-Lipoxygenase | 2 | 2012 | 4 | 0.420 |
Why?
|
| Diastole | 3 | 2024 | 169 | 0.410 |
Why?
|
| Blood Glucose | 8 | 2021 | 1119 | 0.410 |
Why?
|
| Mice, Inbred C57BL | 11 | 2021 | 4351 | 0.400 |
Why?
|
| Nitric Oxide Synthase | 3 | 2008 | 186 | 0.400 |
Why?
|
| Accidental Falls | 1 | 2013 | 104 | 0.400 |
Why?
|
| NF-kappa B | 2 | 2020 | 457 | 0.400 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2013 | 120 | 0.400 |
Why?
|
| Gene Expression Regulation | 7 | 2023 | 2524 | 0.400 |
Why?
|
| Decision Making, Computer-Assisted | 2 | 2011 | 19 | 0.390 |
Why?
|
| Fumarates | 1 | 2011 | 15 | 0.390 |
Why?
|
| Ventricular Septal Rupture | 2 | 2002 | 3 | 0.390 |
Why?
|
| Bradycardia | 3 | 2016 | 59 | 0.390 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2007 | 248 | 0.390 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2006 | 274 | 0.380 |
Why?
|
| Recovery of Function | 2 | 2013 | 437 | 0.380 |
Why?
|
| Lipopolysaccharides | 2 | 2018 | 290 | 0.380 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2011 | 60 | 0.380 |
Why?
|
| Pyrimidines | 1 | 2014 | 373 | 0.380 |
Why?
|
| Valine | 1 | 2011 | 106 | 0.380 |
Why?
|
| Amides | 1 | 2011 | 83 | 0.380 |
Why?
|
| Phosphodiesterase Inhibitors | 4 | 2007 | 52 | 0.380 |
Why?
|
| Fibrosis | 6 | 2020 | 429 | 0.370 |
Why?
|
| Diabetes Mellitus | 4 | 2014 | 848 | 0.370 |
Why?
|
| Glyburide | 2 | 2008 | 22 | 0.370 |
Why?
|
| Hyperlipidemias | 2 | 2012 | 173 | 0.360 |
Why?
|
| Proton Pump Inhibitors | 2 | 2024 | 254 | 0.360 |
Why?
|
| Heparin | 6 | 2003 | 227 | 0.360 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2011 | 78 | 0.350 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2008 | 61 | 0.350 |
Why?
|
| Torsades de Pointes | 1 | 2010 | 6 | 0.340 |
Why?
|
| Atherosclerosis | 4 | 2022 | 831 | 0.340 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 936 | 0.340 |
Why?
|
| Rabbits | 11 | 2007 | 709 | 0.340 |
Why?
|
| Ofloxacin | 1 | 2010 | 32 | 0.340 |
Why?
|
| Drug Synergism | 5 | 2016 | 239 | 0.340 |
Why?
|
| Levofloxacin | 1 | 2010 | 45 | 0.340 |
Why?
|
| Reperfusion Injury | 2 | 2007 | 102 | 0.340 |
Why?
|
| Pyrazines | 1 | 2010 | 73 | 0.330 |
Why?
|
| Arteriosclerosis | 3 | 2004 | 137 | 0.330 |
Why?
|
| Insulin Resistance | 1 | 2014 | 639 | 0.330 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2010 | 79 | 0.330 |
Why?
|
| Aortic Valve | 5 | 2023 | 433 | 0.320 |
Why?
|
| Leukotriene B4 | 1 | 2008 | 7 | 0.310 |
Why?
|
| Incidence | 10 | 2013 | 3043 | 0.310 |
Why?
|
| Sulfonylurea Compounds | 1 | 2008 | 16 | 0.310 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 1309 | 0.310 |
Why?
|
| Endothelium, Vascular | 3 | 2007 | 514 | 0.300 |
Why?
|
| Food-Drug Interactions | 1 | 2008 | 10 | 0.300 |
Why?
|
| Recurrence | 10 | 2013 | 1419 | 0.300 |
Why?
|
| Coffee | 1 | 2008 | 24 | 0.300 |
Why?
|
| Prasugrel Hydrochloride | 2 | 2019 | 21 | 0.300 |
Why?
|
| Transcatheter Aortic Valve Replacement | 2 | 2021 | 195 | 0.300 |
Why?
|
| Azetidines | 1 | 2008 | 55 | 0.300 |
Why?
|
| Logistic Models | 14 | 2020 | 1797 | 0.290 |
Why?
|
| Collateral Circulation | 4 | 2005 | 45 | 0.290 |
Why?
|
| Caffeine | 1 | 2008 | 71 | 0.290 |
Why?
|
| Myocardial Stunning | 3 | 1996 | 21 | 0.290 |
Why?
|
| Prostaglandin D2 | 1 | 2007 | 7 | 0.290 |
Why?
|
| Pericardial Effusion | 3 | 2005 | 64 | 0.290 |
Why?
|
| Clinical Competence | 1 | 2014 | 973 | 0.280 |
Why?
|
| Dyslipidemias | 1 | 2010 | 229 | 0.280 |
Why?
|
| Prospective Studies | 17 | 2022 | 6027 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 2055 | 0.280 |
Why?
|
| CARD Signaling Adaptor Proteins | 2 | 2017 | 43 | 0.280 |
Why?
|
| Oxazoles | 2 | 2017 | 23 | 0.270 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 265 | 0.270 |
Why?
|
| Piperazines | 2 | 2006 | 230 | 0.270 |
Why?
|
| PPAR alpha | 2 | 2017 | 53 | 0.270 |
Why?
|
| Pyrrolidines | 1 | 2006 | 36 | 0.260 |
Why?
|
| Heart Transplantation | 1 | 2013 | 854 | 0.260 |
Why?
|
| Thiophenes | 2 | 2017 | 60 | 0.260 |
Why?
|
| Societies, Medical | 3 | 2020 | 676 | 0.260 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2010 | 111 | 0.260 |
Why?
|
| Pericardium | 2 | 2022 | 82 | 0.250 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 181 | 0.250 |
Why?
|
| Waiting Lists | 1 | 2007 | 225 | 0.250 |
Why?
|
| Accidents, Traffic | 1 | 2006 | 105 | 0.250 |
Why?
|
| Femoral Artery | 4 | 2007 | 190 | 0.250 |
Why?
|
| Hospitalization | 7 | 2022 | 1728 | 0.240 |
Why?
|
| Cells, Cultured | 9 | 2018 | 3042 | 0.240 |
Why?
|
| Glucose | 2 | 2021 | 872 | 0.240 |
Why?
|
| Prostaglandins | 1 | 2005 | 47 | 0.240 |
Why?
|
| Munchausen Syndrome | 1 | 2004 | 4 | 0.240 |
Why?
|
| Ticlopidine | 2 | 2015 | 28 | 0.240 |
Why?
|
| Pericardiocentesis | 2 | 2005 | 16 | 0.240 |
Why?
|
| Tyrosine | 3 | 2011 | 152 | 0.240 |
Why?
|
| Hypotension, Orthostatic | 1 | 2004 | 17 | 0.240 |
Why?
|
| Electric Stimulation Therapy | 1 | 2005 | 101 | 0.240 |
Why?
|
| Gastroparesis | 1 | 2005 | 66 | 0.230 |
Why?
|
| Aortic Coarctation | 1 | 2006 | 105 | 0.230 |
Why?
|
| Heart Failure, Diastolic | 1 | 2024 | 11 | 0.230 |
Why?
|
| Aortic Rupture | 1 | 2006 | 118 | 0.230 |
Why?
|
| Intraoperative Complications | 1 | 2006 | 175 | 0.230 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 6 | 2005 | 105 | 0.230 |
Why?
|
| Cause of Death | 3 | 2018 | 463 | 0.230 |
Why?
|
| Creatinine | 3 | 2021 | 380 | 0.230 |
Why?
|
| Body Weight | 6 | 2012 | 1000 | 0.230 |
Why?
|
| Patient Discharge | 3 | 2006 | 486 | 0.230 |
Why?
|
| Heart Valve Prosthesis | 4 | 2004 | 293 | 0.230 |
Why?
|
| Tetralogy of Fallot | 1 | 2006 | 161 | 0.230 |
Why?
|
| Albumins | 2 | 2021 | 87 | 0.230 |
Why?
|
| Vasodilator Agents | 2 | 2021 | 203 | 0.230 |
Why?
|
| Takotsubo Cardiomyopathy | 2 | 2015 | 17 | 0.220 |
Why?
|
| Analysis of Variance | 7 | 2007 | 1008 | 0.220 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2003 | 6 | 0.220 |
Why?
|
| Bundle of His | 2 | 2022 | 7 | 0.220 |
Why?
|
| Consensus | 4 | 2014 | 606 | 0.220 |
Why?
|
| Necrosis | 5 | 2006 | 205 | 0.220 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 1072 | 0.220 |
Why?
|
| Blood | 2 | 2001 | 105 | 0.220 |
Why?
|
| Radiopharmaceuticals | 5 | 2005 | 155 | 0.210 |
Why?
|
| Phospholipases A2 | 3 | 2010 | 35 | 0.210 |
Why?
|
| Hindlimb | 2 | 2007 | 75 | 0.210 |
Why?
|
| Protective Agents | 2 | 2016 | 31 | 0.210 |
Why?
|
| Hernia, Hiatal | 1 | 2003 | 54 | 0.210 |
Why?
|
| Mice, Knockout | 7 | 2017 | 3718 | 0.210 |
Why?
|
| Potassium Channels | 1 | 2004 | 158 | 0.210 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2004 | 186 | 0.210 |
Why?
|
| Echocardiography, Doppler, Color | 3 | 2004 | 114 | 0.210 |
Why?
|
| Inflammation Mediators | 3 | 2020 | 233 | 0.210 |
Why?
|
| In Vitro Techniques | 7 | 2013 | 966 | 0.210 |
Why?
|
| Drug Administration Schedule | 5 | 2021 | 724 | 0.210 |
Why?
|
| Follow-Up Studies | 10 | 2013 | 5047 | 0.200 |
Why?
|
| Pulmonary Artery | 2 | 1999 | 439 | 0.200 |
Why?
|
| Patients | 1 | 2023 | 121 | 0.200 |
Why?
|
| Cholesterol, LDL | 2 | 2019 | 557 | 0.200 |
Why?
|
| Antacids | 1 | 2022 | 26 | 0.200 |
Why?
|
| Morphine Derivatives | 1 | 2022 | 6 | 0.200 |
Why?
|
| Circulating MicroRNA | 2 | 2019 | 8 | 0.200 |
Why?
|
| Aorta | 1 | 2006 | 542 | 0.200 |
Why?
|
| Pyrazoles | 3 | 2024 | 303 | 0.200 |
Why?
|
| Apyrase | 1 | 2022 | 18 | 0.200 |
Why?
|
| Histamine H2 Antagonists | 1 | 2022 | 49 | 0.200 |
Why?
|
| Ketosis | 1 | 2021 | 15 | 0.190 |
Why?
|
| Hematoxylin | 1 | 2021 | 7 | 0.190 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2021 | 8 | 0.190 |
Why?
|
| Periodic Acid | 1 | 2021 | 7 | 0.190 |
Why?
|
| Digoxin | 1 | 2021 | 41 | 0.190 |
Why?
|
| Ultrasonics | 1 | 2001 | 36 | 0.190 |
Why?
|
| Fibrinolysis | 1 | 2001 | 38 | 0.190 |
Why?
|
| Heart Rupture | 1 | 2001 | 3 | 0.190 |
Why?
|
| Electrodes, Implanted | 1 | 2002 | 163 | 0.190 |
Why?
|
| Terminology as Topic | 2 | 2017 | 229 | 0.190 |
Why?
|
| Disease Progression | 6 | 2020 | 2023 | 0.190 |
Why?
|
| Hypertension | 5 | 2018 | 1286 | 0.180 |
Why?
|
| Enzyme Induction | 2 | 2014 | 103 | 0.180 |
Why?
|
| Cystatin C | 1 | 2021 | 49 | 0.180 |
Why?
|
| Pulmonary Embolism | 1 | 2003 | 174 | 0.180 |
Why?
|
| Isoquinolines | 2 | 2012 | 40 | 0.180 |
Why?
|
| Gadolinium | 2 | 2018 | 103 | 0.180 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 50 | 0.180 |
Why?
|
| Electroacupuncture | 1 | 2020 | 8 | 0.180 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2002 | 156 | 0.180 |
Why?
|
| Syndrome | 4 | 2007 | 1115 | 0.180 |
Why?
|
| Muscle, Skeletal | 3 | 2014 | 936 | 0.180 |
Why?
|
| Aortic Aneurysm | 1 | 2003 | 224 | 0.180 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 69 | 0.180 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 13 | 0.180 |
Why?
|
| Survival Rate | 7 | 2018 | 1997 | 0.170 |
Why?
|
| Inflammation | 3 | 2022 | 1401 | 0.170 |
Why?
|
| Odds Ratio | 7 | 2020 | 1244 | 0.170 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2010 | 69 | 0.170 |
Why?
|
| Dobutamine | 2 | 2019 | 55 | 0.170 |
Why?
|
| Sonication | 1 | 1999 | 8 | 0.170 |
Why?
|
| Journal Impact Factor | 1 | 2020 | 22 | 0.170 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2020 | 151 | 0.170 |
Why?
|
| Secondary Prevention | 3 | 2019 | 212 | 0.170 |
Why?
|
| Cohort Studies | 6 | 2018 | 4702 | 0.170 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2019 | 52 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2021 | 796 | 0.170 |
Why?
|
| Abnormalities, Multiple | 1 | 2006 | 962 | 0.170 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2021 | 154 | 0.170 |
Why?
|
| Fibrin | 1 | 1999 | 67 | 0.170 |
Why?
|
| Down-Regulation | 2 | 2018 | 697 | 0.160 |
Why?
|
| Arterio-Arterial Fistula | 1 | 1999 | 8 | 0.160 |
Why?
|
| Swine | 3 | 2018 | 1155 | 0.160 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2015 | 218 | 0.160 |
Why?
|
| Smoking | 3 | 2007 | 1031 | 0.160 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 252 | 0.160 |
Why?
|
| Shock, Cardiogenic | 4 | 2020 | 187 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 238 | 0.160 |
Why?
|
| Endoglin | 1 | 2019 | 22 | 0.160 |
Why?
|
| Angina Pectoris | 3 | 1996 | 57 | 0.160 |
Why?
|
| Blood Pressure | 5 | 2013 | 1325 | 0.160 |
Why?
|
| Blotting, Western | 2 | 2012 | 1100 | 0.160 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2010 | 29 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2019 | 53 | 0.160 |
Why?
|
| Hemorrhage | 1 | 2022 | 458 | 0.160 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 78 | 0.160 |
Why?
|
| Multimorbidity | 1 | 2018 | 20 | 0.160 |
Why?
|
| Extracellular Vesicles | 1 | 2019 | 45 | 0.160 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 68 | 0.160 |
Why?
|
| Aorta, Thoracic | 1 | 2003 | 520 | 0.160 |
Why?
|
| Cyclooxygenase 1 | 2 | 2010 | 40 | 0.150 |
Why?
|
| Cardiomyopathy, Alcoholic | 1 | 2018 | 4 | 0.150 |
Why?
|
| Receptors, Opioid, delta | 2 | 2009 | 12 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2013 | 523 | 0.150 |
Why?
|
| Erythrocytes | 1 | 2019 | 206 | 0.150 |
Why?
|
| Radiographic Image Enhancement | 1 | 2018 | 41 | 0.150 |
Why?
|
| RNA, Messenger | 3 | 2016 | 2809 | 0.150 |
Why?
|
| Statistics as Topic | 3 | 2004 | 250 | 0.150 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2006 | 238 | 0.150 |
Why?
|
| Membrane Proteins | 3 | 2012 | 1521 | 0.150 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 143 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 2391 | 0.150 |
Why?
|
| Dexmedetomidine | 1 | 2018 | 44 | 0.150 |
Why?
|
| Receptors, Purinergic P1 | 2 | 2008 | 10 | 0.150 |
Why?
|
| Troponin | 1 | 2018 | 71 | 0.150 |
Why?
|
| Models, Cardiovascular | 3 | 2010 | 180 | 0.150 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2009 | 84 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 426 | 0.150 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2017 | 24 | 0.150 |
Why?
|
| Serum Albumin | 1 | 1998 | 107 | 0.150 |
Why?
|
| Combined Modality Therapy | 7 | 2003 | 1237 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2018 | 70 | 0.150 |
Why?
|
| L-Selectin | 1 | 1997 | 21 | 0.140 |
Why?
|
| E-Selectin | 1 | 1997 | 42 | 0.140 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2010 | 88 | 0.140 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 152 | 0.140 |
Why?
|
| Iliac Artery | 1 | 1998 | 92 | 0.140 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2018 | 147 | 0.140 |
Why?
|
| Riots | 1 | 1997 | 2 | 0.140 |
Why?
|
| Hypnotics and Sedatives | 1 | 2018 | 135 | 0.140 |
Why?
|
| Arabs | 1 | 1997 | 29 | 0.140 |
Why?
|
| P-Selectin | 1 | 1997 | 77 | 0.140 |
Why?
|
| Infarction | 1 | 1997 | 23 | 0.140 |
Why?
|
| Cardiovascular System | 1 | 2018 | 99 | 0.140 |
Why?
|
| Oligosaccharides | 1 | 1997 | 76 | 0.140 |
Why?
|
| Radiography | 5 | 2006 | 822 | 0.140 |
Why?
|
| Pattern Recognition, Automated | 2 | 2013 | 48 | 0.140 |
Why?
|
| Rats, Zucker | 1 | 2016 | 41 | 0.140 |
Why?
|
| Gangliosides | 1 | 1997 | 63 | 0.140 |
Why?
|
| Ubiquinone | 1 | 1996 | 24 | 0.140 |
Why?
|
| Liraglutide | 1 | 2016 | 14 | 0.140 |
Why?
|
| Comorbidity | 2 | 2018 | 1495 | 0.140 |
Why?
|
| Intramolecular Oxidoreductases | 2 | 2008 | 56 | 0.140 |
Why?
|
| Israel | 4 | 2002 | 44 | 0.140 |
Why?
|
| Equipment Design | 1 | 2019 | 601 | 0.140 |
Why?
|
| Acute Kidney Injury | 2 | 1994 | 613 | 0.130 |
Why?
|
| Blood Platelets | 1 | 2019 | 333 | 0.130 |
Why?
|
| Arteries | 1 | 1997 | 221 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 653 | 0.130 |
Why?
|
| Violence | 1 | 1997 | 112 | 0.130 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2017 | 109 | 0.130 |
Why?
|
| Staining and Labeling | 1 | 1997 | 183 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 159 | 0.130 |
Why?
|
| Observer Variation | 3 | 2014 | 295 | 0.130 |
Why?
|
| United States | 7 | 2022 | 10646 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 622 | 0.130 |
Why?
|
| Cell Survival | 3 | 2017 | 808 | 0.130 |
Why?
|
| Nicotinic Agonists | 1 | 1996 | 44 | 0.130 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2008 | 136 | 0.130 |
Why?
|
| Coitus | 1 | 2015 | 20 | 0.130 |
Why?
|
| Pleasure | 1 | 2015 | 12 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 810 | 0.130 |
Why?
|
| Rest | 1 | 2015 | 59 | 0.130 |
Why?
|
| Phospholipases A | 2 | 2006 | 39 | 0.130 |
Why?
|
| Injections, Intraperitoneal | 1 | 2015 | 73 | 0.120 |
Why?
|
| RNA Interference | 2 | 2017 | 496 | 0.120 |
Why?
|
| Texas | 4 | 2013 | 3562 | 0.120 |
Why?
|
| Chi-Square Distribution | 5 | 2011 | 586 | 0.120 |
Why?
|
| Parkinson Disease | 1 | 2002 | 671 | 0.120 |
Why?
|
| Risk | 1 | 2017 | 745 | 0.120 |
Why?
|
| Creatine Kinase, MB Form | 2 | 2012 | 18 | 0.120 |
Why?
|
| Contrast Media | 4 | 2017 | 470 | 0.120 |
Why?
|
| Hyperglycemia | 1 | 2017 | 221 | 0.120 |
Why?
|
| Preoperative Care | 3 | 2012 | 350 | 0.120 |
Why?
|
| Nicotine | 1 | 1996 | 141 | 0.120 |
Why?
|
| Angina Pectoris, Variant | 1 | 2014 | 1 | 0.120 |
Why?
|
| Models, Biological | 2 | 2012 | 1443 | 0.120 |
Why?
|
| Caspase 3 | 2 | 2017 | 131 | 0.120 |
Why?
|
| Diet, Western | 1 | 2014 | 17 | 0.120 |
Why?
|
| Immune Complex Diseases | 1 | 1994 | 5 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2016 | 393 | 0.120 |
Why?
|
| Multivariate Analysis | 8 | 2007 | 1412 | 0.120 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2014 | 2 | 0.120 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2014 | 3 | 0.120 |
Why?
|
| Random Allocation | 3 | 2005 | 427 | 0.120 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2014 | 10 | 0.120 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2014 | 10 | 0.120 |
Why?
|
| RNA | 1 | 2018 | 570 | 0.120 |
Why?
|
| Protein Binding | 1 | 2018 | 1741 | 0.120 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1687 | 0.120 |
Why?
|
| Echocardiography, Doppler | 4 | 2005 | 170 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 151 | 0.110 |
Why?
|
| Ultrasonography | 4 | 2001 | 940 | 0.110 |
Why?
|
| Stem Cells | 1 | 2019 | 700 | 0.110 |
Why?
|
| Ezetimibe | 2 | 2019 | 95 | 0.110 |
Why?
|
| Congresses as Topic | 2 | 2019 | 169 | 0.110 |
Why?
|
| Hemarthrosis | 1 | 1993 | 2 | 0.110 |
Why?
|
| Organ Size | 2 | 2010 | 412 | 0.110 |
Why?
|
| Age Factors | 5 | 2024 | 2802 | 0.110 |
Why?
|
| Regression Analysis | 4 | 2005 | 767 | 0.110 |
Why?
|
| Calcium | 2 | 2010 | 1095 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2013 | 428 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 350 | 0.110 |
Why?
|
| Quinazolines | 1 | 2014 | 175 | 0.110 |
Why?
|
| Benzopyrans | 1 | 2013 | 19 | 0.110 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2012 | 130 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 98 | 0.110 |
Why?
|
| Stellate Ganglion | 1 | 2013 | 9 | 0.110 |
Why?
|
| Tachycardia, Sinus | 1 | 2013 | 7 | 0.110 |
Why?
|
| Ethanolamines | 1 | 2013 | 30 | 0.110 |
Why?
|
| Atenolol | 1 | 2013 | 43 | 0.110 |
Why?
|
| Survival Analysis | 4 | 2018 | 1472 | 0.110 |
Why?
|
| Metabolic Syndrome | 1 | 2016 | 329 | 0.110 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 1992 | 24 | 0.100 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 1999 | 664 | 0.100 |
Why?
|
| Cardiology | 2 | 2016 | 472 | 0.100 |
Why?
|
| Mammary Arteries | 1 | 1992 | 26 | 0.100 |
Why?
|
| Diuretics | 1 | 2013 | 158 | 0.100 |
Why?
|
| Prevalence | 5 | 2011 | 2404 | 0.100 |
Why?
|
| Genetic Pleiotropy | 1 | 2012 | 24 | 0.100 |
Why?
|
| Microspheres | 2 | 2003 | 70 | 0.100 |
Why?
|
| Chromosomes, Mammalian | 1 | 2012 | 41 | 0.100 |
Why?
|
| Transcriptome | 1 | 2018 | 902 | 0.100 |
Why?
|
| Anesthetics, Local | 1 | 2013 | 80 | 0.100 |
Why?
|
| Arteriovenous Fistula | 1 | 1992 | 56 | 0.100 |
Why?
|
| Valsartan | 1 | 2011 | 21 | 0.100 |
Why?
|
| Biomarkers | 6 | 2020 | 2942 | 0.100 |
Why?
|
| Dogs | 4 | 2003 | 765 | 0.100 |
Why?
|
| Double-Blind Method | 4 | 2018 | 1590 | 0.100 |
Why?
|
| Nerve Block | 1 | 2013 | 68 | 0.100 |
Why?
|
| Renin | 1 | 2011 | 89 | 0.100 |
Why?
|
| Brugada Syndrome | 1 | 2011 | 9 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 281 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 3 | 2020 | 864 | 0.090 |
Why?
|
| Chronic Disease | 3 | 2022 | 1161 | 0.090 |
Why?
|
| Troponin I | 1 | 2012 | 96 | 0.090 |
Why?
|
| Mice, Inbred Strains | 1 | 2011 | 311 | 0.090 |
Why?
|
| Radionuclide Imaging | 3 | 2005 | 151 | 0.090 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 2 | 2002 | 26 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 413 | 0.090 |
Why?
|
| Polygeline | 2 | 2001 | 2 | 0.090 |
Why?
|
| Emergency Medical Services | 2 | 2014 | 434 | 0.090 |
Why?
|
| Plasma Substitutes | 2 | 2001 | 7 | 0.090 |
Why?
|
| Emergencies | 1 | 2012 | 174 | 0.090 |
Why?
|
| Diabetic Retinopathy | 1 | 2013 | 155 | 0.090 |
Why?
|
| CREB-Binding Protein | 1 | 2010 | 63 | 0.090 |
Why?
|
| Sitagliptin Phosphate | 1 | 2010 | 7 | 0.090 |
Why?
|
| Veterans | 1 | 2022 | 1731 | 0.090 |
Why?
|
| Hypoxia | 1 | 2012 | 247 | 0.090 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 94 | 0.090 |
Why?
|
| Retina | 1 | 2013 | 456 | 0.090 |
Why?
|
| Triglycerides | 1 | 2012 | 561 | 0.090 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 398 | 0.080 |
Why?
|
| Sex Factors | 4 | 2020 | 1260 | 0.080 |
Why?
|
| Cholesterol | 1 | 2012 | 525 | 0.080 |
Why?
|
| Myocardial Contraction | 4 | 2009 | 260 | 0.080 |
Why?
|
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2009 | 20 | 0.080 |
Why?
|
| Culture Media | 1 | 2010 | 182 | 0.080 |
Why?
|
| Lipids | 1 | 2012 | 515 | 0.080 |
Why?
|
| Insulin | 1 | 2014 | 1200 | 0.080 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 351 | 0.080 |
Why?
|
| Sodium Chloride | 2 | 1999 | 95 | 0.080 |
Why?
|
| Decanoic Acids | 1 | 2008 | 2 | 0.080 |
Why?
|
| Hydroxy Acids | 1 | 2008 | 3 | 0.080 |
Why?
|
| Calcium Channel Blockers | 2 | 2022 | 113 | 0.080 |
Why?
|
| Models, Animal | 2 | 2012 | 464 | 0.080 |
Why?
|
| KATP Channels | 1 | 2008 | 6 | 0.080 |
Why?
|
| Cell Line | 2 | 2013 | 2769 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 372 | 0.080 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2009 | 87 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 2010 | 284 | 0.080 |
Why?
|
| Myocarditis | 1 | 1989 | 119 | 0.080 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2008 | 52 | 0.080 |
Why?
|
| Tyrphostins | 1 | 2008 | 14 | 0.080 |
Why?
|
| Ligation | 1 | 2008 | 132 | 0.080 |
Why?
|
| Mitochondria, Heart | 1 | 2008 | 60 | 0.080 |
Why?
|
| Drug Combinations | 2 | 2007 | 269 | 0.080 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 49 | 0.080 |
Why?
|
| Fluorocarbons | 2 | 1999 | 56 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 261 | 0.080 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2006 | 60 | 0.080 |
Why?
|
| Janus Kinases | 1 | 2008 | 31 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 340 | 0.080 |
Why?
|
| Propranolol | 1 | 2008 | 128 | 0.070 |
Why?
|
| Sildenafil Citrate | 2 | 2006 | 51 | 0.070 |
Why?
|
| Sulfones | 2 | 2006 | 66 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1290 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2006 | 169 | 0.070 |
Why?
|
| Purines | 2 | 2006 | 107 | 0.070 |
Why?
|
| Serine | 1 | 2008 | 172 | 0.070 |
Why?
|
| Angioplasty, Balloon | 2 | 2011 | 161 | 0.070 |
Why?
|
| Theophylline | 1 | 2007 | 29 | 0.070 |
Why?
|
| Creatine Kinase, BB Form | 1 | 2007 | 5 | 0.070 |
Why?
|
| Survival | 1 | 2007 | 19 | 0.070 |
Why?
|
| 5'-Nucleotidase | 1 | 2007 | 15 | 0.070 |
Why?
|
| Butadienes | 1 | 2007 | 19 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 228 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2007 | 38 | 0.070 |
Why?
|
| Creatine Kinase | 2 | 1998 | 54 | 0.070 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 154 | 0.070 |
Why?
|
| CD36 Antigens | 1 | 2007 | 35 | 0.070 |
Why?
|
| Models, Chemical | 1 | 2007 | 85 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2008 | 179 | 0.070 |
Why?
|
| Nitroso Compounds | 1 | 2006 | 8 | 0.070 |
Why?
|
| Colitis, Ulcerative | 1 | 1989 | 207 | 0.070 |
Why?
|
| Biotin | 1 | 2006 | 41 | 0.070 |
Why?
|
| Nitriles | 1 | 2007 | 145 | 0.070 |
Why?
|
| Inositol Polyphosphate 5-Phosphatases | 1 | 2006 | 6 | 0.070 |
Why?
|
| Constriction, Pathologic | 3 | 1997 | 237 | 0.070 |
Why?
|
| Oncogene Protein v-akt | 1 | 2006 | 30 | 0.070 |
Why?
|
| Amidines | 1 | 2006 | 1 | 0.070 |
Why?
|
| Benzylamines | 1 | 2006 | 16 | 0.070 |
Why?
|
| Gene Expression | 1 | 2011 | 1565 | 0.070 |
Why?
|
| Hypercalcemia | 1 | 2006 | 39 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 1999 | 752 | 0.060 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2006 | 100 | 0.060 |
Why?
|
| Alanine | 1 | 2006 | 181 | 0.060 |
Why?
|
| Forecasting | 2 | 2005 | 354 | 0.060 |
Why?
|
| Obesity | 1 | 2016 | 2227 | 0.060 |
Why?
|
| Prostaglandin-E Synthases | 1 | 2005 | 11 | 0.060 |
Why?
|
| Exercise | 2 | 2005 | 812 | 0.060 |
Why?
|
| Isoxazoles | 1 | 2005 | 31 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 715 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 1584 | 0.060 |
Why?
|
| Regional Blood Flow | 3 | 2007 | 213 | 0.060 |
Why?
|
| Reference Values | 2 | 2003 | 697 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2013 | 1389 | 0.060 |
Why?
|
| Mitral Valve | 2 | 2004 | 246 | 0.060 |
Why?
|
| Polyethylene Terephthalates | 1 | 2004 | 40 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 1 | 2004 | 142 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 571 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2018 | 423 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 304 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2007 | 439 | 0.060 |
Why?
|
| Brachiocephalic Trunk | 1 | 2004 | 35 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2012 | 330 | 0.060 |
Why?
|
| Swine Diseases | 1 | 2004 | 36 | 0.060 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2004 | 95 | 0.060 |
Why?
|
| Blood Flow Velocity | 3 | 2005 | 450 | 0.060 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2004 | 62 | 0.060 |
Why?
|
| Pneumonia | 2 | 2020 | 324 | 0.050 |
Why?
|
| Pyridones | 1 | 2024 | 112 | 0.050 |
Why?
|
| Catheter Ablation | 2 | 2004 | 233 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2003 | 93 | 0.050 |
Why?
|
| Prosthesis Failure | 2 | 2004 | 159 | 0.050 |
Why?
|
| Age of Onset | 2 | 2002 | 581 | 0.050 |
Why?
|
| Immersion | 1 | 2002 | 8 | 0.050 |
Why?
|
| Clot Retraction | 1 | 2002 | 6 | 0.050 |
Why?
|
| Physical Examination | 1 | 2004 | 165 | 0.050 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2004 | 796 | 0.050 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2003 | 59 | 0.050 |
Why?
|
| Transfection | 2 | 2017 | 1068 | 0.050 |
Why?
|
| Cardiac Tamponade | 2 | 2005 | 37 | 0.050 |
Why?
|
| Pregnancy | 1 | 2015 | 7159 | 0.050 |
Why?
|
| 3' Untranslated Regions | 2 | 2013 | 165 | 0.050 |
Why?
|
| Heart Septum | 1 | 2002 | 55 | 0.050 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2004 | 193 | 0.050 |
Why?
|
| Network Meta-Analysis | 1 | 2022 | 37 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2002 | 3239 | 0.050 |
Why?
|
| Health Personnel | 1 | 2006 | 494 | 0.050 |
Why?
|
| Streptozocin | 1 | 2021 | 24 | 0.050 |
Why?
|
| Homocysteine | 1 | 2002 | 121 | 0.050 |
Why?
|
| Esophagus | 1 | 2003 | 213 | 0.050 |
Why?
|
| Body Composition | 1 | 2004 | 513 | 0.050 |
Why?
|
| Corticosterone | 1 | 2021 | 60 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 1004 | 0.050 |
Why?
|
| Ketones | 1 | 2021 | 24 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 1678 | 0.050 |
Why?
|
| Milrinone | 1 | 2001 | 30 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2005 | 534 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 180 | 0.050 |
Why?
|
| Hospital Costs | 1 | 2022 | 178 | 0.050 |
Why?
|
| Colloids | 1 | 2000 | 17 | 0.040 |
Why?
|
| Epinephrine | 1 | 2021 | 175 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 28 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2002 | 295 | 0.040 |
Why?
|
| Mortality | 1 | 2022 | 228 | 0.040 |
Why?
|
| Water | 1 | 2021 | 182 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 713 | 0.040 |
Why?
|
| Vascular Surgical Procedures | 1 | 2006 | 565 | 0.040 |
Why?
|
| Mass Screening | 2 | 2022 | 785 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 154 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2020 | 91 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 135 | 0.040 |
Why?
|
| Embolism, Air | 1 | 2000 | 25 | 0.040 |
Why?
|
| Suction | 1 | 2000 | 58 | 0.040 |
Why?
|
| Ventricular Dysfunction | 1 | 2000 | 24 | 0.040 |
Why?
|
| Solubility | 1 | 1999 | 132 | 0.040 |
Why?
|
| Endocarditis | 1 | 2020 | 101 | 0.040 |
Why?
|
| Systole | 1 | 2000 | 196 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 2 | 1998 | 258 | 0.040 |
Why?
|
| Kinetics | 1 | 2001 | 1313 | 0.040 |
Why?
|
| Premedication | 1 | 1999 | 43 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2002 | 406 | 0.040 |
Why?
|
| Hemostasis | 1 | 2019 | 69 | 0.040 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2000 | 133 | 0.040 |
Why?
|
| Ulcer | 1 | 1999 | 48 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 350 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 1998 | 537 | 0.040 |
Why?
|
| Heart Valve Diseases | 1 | 2000 | 166 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2022 | 368 | 0.040 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 2 | 2009 | 3 | 0.040 |
Why?
|
| Disease Management | 1 | 2002 | 513 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2020 | 1171 | 0.040 |
Why?
|
| Denmark | 1 | 2018 | 32 | 0.040 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2003 | 533 | 0.040 |
Why?
|
| Serum Albumin, Human | 1 | 1998 | 10 | 0.040 |
Why?
|
| Soft Tissue Injuries | 1 | 1998 | 11 | 0.040 |
Why?
|
| Hematoma | 1 | 1999 | 93 | 0.040 |
Why?
|
| Atherectomy, Coronary | 1 | 1997 | 9 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1999 | 117 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 1008 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 117 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 1998 | 279 | 0.040 |
Why?
|
| Saphenous Vein | 1 | 1997 | 53 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1998 | 126 | 0.040 |
Why?
|
| Sudan | 1 | 1997 | 4 | 0.040 |
Why?
|
| Los Angeles | 1 | 1997 | 17 | 0.040 |
Why?
|
| Coroners and Medical Examiners | 1 | 1997 | 15 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2018 | 399 | 0.040 |
Why?
|
| Cats | 1 | 1997 | 116 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2021 | 472 | 0.040 |
Why?
|
| Tetrazolium Salts | 1 | 1997 | 15 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 1998 | 84 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2017 | 78 | 0.030 |
Why?
|
| Aging | 1 | 2024 | 1175 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2017 | 39 | 0.030 |
Why?
|
| Cytochromes c | 1 | 2017 | 51 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 1099 | 0.030 |
Why?
|
| Coenzymes | 1 | 1996 | 12 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2017 | 189 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2007 | 2584 | 0.030 |
Why?
|
| Data Collection | 1 | 1999 | 383 | 0.030 |
Why?
|
| Doxorubicin | 1 | 1998 | 299 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2020 | 363 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 1997 | 318 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2019 | 226 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2017 | 795 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 1997 | 318 | 0.030 |
Why?
|
| Species Specificity | 1 | 1997 | 548 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1998 | 214 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 1998 | 120 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1998 | 232 | 0.030 |
Why?
|
| Cardiac Output, Low | 1 | 1996 | 66 | 0.030 |
Why?
|
| Cineradiography | 1 | 1996 | 3 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 375 | 0.030 |
Why?
|
| Running | 1 | 1996 | 36 | 0.030 |
Why?
|
| Coronary Care Units | 1 | 1996 | 36 | 0.030 |
Why?
|
| Electrodes | 1 | 1996 | 97 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 269 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1996 | 235 | 0.030 |
Why?
|
| Long QT Syndrome | 1 | 1996 | 85 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 489 | 0.030 |
Why?
|
| Neutrophils | 1 | 1997 | 373 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 381 | 0.030 |
Why?
|
| Rural Population | 1 | 1997 | 251 | 0.030 |
Why?
|
| Skin | 1 | 1998 | 506 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2007 | 335 | 0.030 |
Why?
|
| Genotype | 2 | 2017 | 2533 | 0.030 |
Why?
|
| Cytokines | 1 | 2020 | 1282 | 0.030 |
Why?
|
| Purkinje Fibers | 1 | 1993 | 6 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2020 | 842 | 0.030 |
Why?
|
| Estradiol | 1 | 1996 | 535 | 0.030 |
Why?
|
| Reperfusion | 1 | 1993 | 25 | 0.030 |
Why?
|
| Mitral Valve Prolapse | 1 | 1993 | 28 | 0.030 |
Why?
|
| Hyperhomocysteinemia | 2 | 2004 | 38 | 0.030 |
Why?
|
| Serum Sickness | 1 | 1993 | 2 | 0.030 |
Why?
|
| Death, Sudden | 1 | 1993 | 45 | 0.030 |
Why?
|
| Rats, Inbred Dahl | 1 | 2013 | 3 | 0.030 |
Why?
|
| Nebivolol | 1 | 2013 | 4 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3370 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2013 | 26 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 1993 | 60 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 861 | 0.030 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2013 | 31 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 2013 | 180 | 0.030 |
Why?
|
| Hypotension | 1 | 1994 | 177 | 0.030 |
Why?
|
| Antioxidants | 1 | 1995 | 338 | 0.030 |
Why?
|
| Cineangiography | 2 | 2004 | 15 | 0.030 |
Why?
|
| Thoracic Injuries | 1 | 1993 | 91 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2013 | 169 | 0.030 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2012 | 15 | 0.020 |
Why?
|
| Linear Models | 1 | 1994 | 669 | 0.020 |
Why?
|
| Exercise Test | 2 | 2005 | 249 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2013 | 384 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2012 | 136 | 0.020 |
Why?
|
| Leptin | 1 | 2013 | 211 | 0.020 |
Why?
|
| Adiponectin | 1 | 2012 | 109 | 0.020 |
Why?
|
| Heart Arrest | 1 | 1996 | 340 | 0.020 |
Why?
|
| Jaundice | 1 | 1991 | 27 | 0.020 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1993 | 209 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 238 | 0.020 |
Why?
|
| Angiography | 2 | 2004 | 215 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2002 | 70 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 481 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 1290 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2012 | 260 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 1386 | 0.020 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2009 | 13 | 0.020 |
Why?
|
| Indomethacin | 1 | 1989 | 84 | 0.020 |
Why?
|
| Homozygote | 2 | 2002 | 532 | 0.020 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2009 | 62 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2008 | 30 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 243 | 0.020 |
Why?
|
| Sepsis | 1 | 2012 | 477 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2014 | 752 | 0.020 |
Why?
|
| Hyperemia | 1 | 2007 | 25 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 4220 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2007 | 189 | 0.020 |
Why?
|
| Vasodilation | 1 | 2007 | 191 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 197 | 0.020 |
Why?
|
| Organotechnetium Compounds | 1 | 2005 | 12 | 0.020 |
Why?
|
| Organophosphorus Compounds | 1 | 2005 | 22 | 0.020 |
Why?
|
| Internationality | 1 | 2006 | 129 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2005 | 35 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2005 | 145 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2005 | 66 | 0.020 |
Why?
|
| Isometric Contraction | 1 | 2005 | 22 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2007 | 241 | 0.020 |
Why?
|
| Cell Count | 1 | 2005 | 250 | 0.020 |
Why?
|
| Plasminogen Activators | 1 | 2004 | 20 | 0.020 |
Why?
|
| Safety | 1 | 2005 | 218 | 0.010 |
Why?
|
| Body Surface Area | 1 | 2004 | 31 | 0.010 |
Why?
|
| Telecommunications | 1 | 2004 | 19 | 0.010 |
Why?
|
| Unnecessary Procedures | 1 | 2004 | 56 | 0.010 |
Why?
|
| Adolescent | 1 | 2002 | 19096 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2004 | 169 | 0.010 |
Why?
|
| Ventricular Fibrillation | 1 | 2004 | 51 | 0.010 |
Why?
|
| Aortography | 1 | 2004 | 200 | 0.010 |
Why?
|
| Edema | 1 | 2004 | 136 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 421 | 0.010 |
Why?
|
| Ethanol | 1 | 2004 | 162 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2005 | 369 | 0.010 |
Why?
|
| Radionuclide Ventriculography | 1 | 2001 | 5 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2001 | 3 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 2001 | 14 | 0.010 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2001 | 22 | 0.010 |
Why?
|
| Transducers | 1 | 2001 | 25 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 2000 | 43 | 0.010 |
Why?
|
| Retreatment | 1 | 2000 | 88 | 0.010 |
Why?
|
| Software | 1 | 2004 | 674 | 0.010 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 1999 | 19 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1999 | 713 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1998 | 391 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1998 | 136 | 0.010 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2000 | 274 | 0.010 |
Why?
|
| Patient Selection | 1 | 2001 | 684 | 0.010 |
Why?
|
| Folic Acid | 1 | 1999 | 292 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1998 | 355 | 0.010 |
Why?
|
| Aortic Diseases | 1 | 1999 | 197 | 0.010 |
Why?
|
| Tilt-Table Test | 1 | 1996 | 9 | 0.010 |
Why?
|
| Exercise Tolerance | 1 | 1996 | 75 | 0.010 |
Why?
|
| Diltiazem | 1 | 1994 | 13 | 0.010 |
Why?
|
| Verapamil | 1 | 1994 | 52 | 0.010 |
Why?
|
| Alleles | 1 | 1999 | 1603 | 0.010 |
Why?
|
| Young Adult | 1 | 2008 | 8835 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1993 | 269 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 1991 | 9 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1991 | 101 | 0.010 |
Why?
|
| Bilirubin | 1 | 1991 | 121 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1999 | 3074 | 0.010 |
Why?
|
| Mutation | 1 | 2002 | 5763 | 0.000 |
Why?
|